1
|
Ceccarelli M, D'Andrea G, Micheli L, Tirone F. Deletion of Btg1 Induces Prmt1-Dependent Apoptosis and Increased Stemness in Shh-Type Medulloblastoma Cells Without Affecting Tumor Frequency. Front Oncol 2020; 10:226. [PMID: 32231994 PMCID: PMC7082329 DOI: 10.3389/fonc.2020.00226] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Accepted: 02/10/2020] [Indexed: 12/16/2022] Open
Abstract
About 30% of medulloblastomas (MBs), a tumor of the cerebellum, arise from cerebellar granule cell precursors (GCPs) undergoing transformation following activation of the Sonic hedgehog (Shh) pathway. To study this process, we generated a new MB model by crossing Patched1 heterozygous (Ptch1+/−) mice, which develop spontaneous Shh-type MBs, with mice lacking B-cell translocation gene 1 (Btg1), a regulator of cerebellar development. In MBs developing in Ptch1+/− mice, deletion of Btg1 does not alter tumor and lesion frequencies, nor affect the proliferation of neoplastic precursor cells. However, in both tumors and lesions arising in Ptch1+/− mice, ablation of Btg1 increases by about 25% the apoptotic neoplastic precursor cells, as judged by positivity to activated caspase-3. Moreover, although Btg1 ablation in early postnatal GCPs, developing in the external granule cell layer, leads to a significant increase of proliferation, and decrease of differentiation, relative to wild-type, no synergy occurs with the Ptch1+/− mutation. However, Btg1 deletion greatly increases apoptosis in postnatal GCPs, with strong synergy between Btg1-null and Ptch1+/− mutations. That pronounced increase of apoptosis observed in Ptch1+/−/Btg1 knockout young or neoplastic GCPs may be responsible for the lack of effect of Btg1 ablation on tumorigenesis. This increased apoptosis may be a consequence of increased expression of protein arginine methyltransferase 1 (Prmt1) protein that we observe in Btg1 knockout/Ptch1+/− MBs. In fact, apoptotic genes, such as BAD, are targets of Prmt1. Moreover, in Btg1-null MBs, we observed a two-fold increase of cells positive to CD15, which labels tumor stem cells, raising the possibility of activation of quiescent tumor cells, known for their role in long-term resistance to treatment and relapses. Thus, Btg1 appears to play a role in cerebellar tumorigenesis by regulating the balance between apoptosis and proliferation during MB development, also influencing the number of tumor stem cells.
Collapse
Affiliation(s)
- Manuela Ceccarelli
- Institute of Biochemistry and Cell Biology, National Research Council (IBBC-CNR), Rome, Italy
| | - Giorgio D'Andrea
- Institute of Biochemistry and Cell Biology, National Research Council (IBBC-CNR), Rome, Italy
| | - Laura Micheli
- Institute of Biochemistry and Cell Biology, National Research Council (IBBC-CNR), Rome, Italy
| | - Felice Tirone
- Institute of Biochemistry and Cell Biology, National Research Council (IBBC-CNR), Rome, Italy
| |
Collapse
|
2
|
Presutti D, Ceccarelli M, Micheli L, Papoff G, Santini S, Samperna S, Lalli C, Zentilin L, Ruberti G, Tirone F. Tis21-gene therapy inhibits medulloblastoma growth in a murine allograft model. PLoS One 2018. [PMID: 29538458 PMCID: PMC5851620 DOI: 10.1371/journal.pone.0194206] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Medulloblastoma (MB), the tumor of the cerebellum, is the most frequent brain cancer in childhood and a major cause of pediatric mortality. Based on gene profiling, four MB subgroups have been identified, i.e., Wnt or Sonic Hedgehog (Shh) types, and subgroup 3 or 4. The Shh-type MB has been shown to arise from the cerebellar precursors of granule neurons (GCPs), where a hyperactivation of the Shh pathway leads to their neoplastic transformation. We have previously shown that the gene Tis21 (PC3/Btg2) inhibits the proliferation and promotes the differentiation and migration of GCPs. Moreover, the overexpression or the deletion of Tis21 in Patched1 heterozygous mice, a model of spontaneous Shh-type MB, highly reduces or increases, respectively, the frequency of MB. Here we tested whether Tis21 can inhibit MB allografts. Athymic nude mice were subcutaneously grafted with MB cells explanted from Patched1 heterozygous mice. MB allografts were then injected with adeno-associated viruses either carrying Tis21 (AAV-Tis21) or empty (AAV-CBA). We observed that the treatment with AAV-Tis21 significantly inhibited the growth of tumor nodules, as judged by their volume, and reduced the number of proliferating tumor cells (labeled with Ki67 or BrdU), relative to AAV-CBA-treated control mice. In parallel, AAV-Tis21 increased significantly tumor cells labeled with early and late neural differentiation markers. Overall the results suggest that Tis21-gene therapy slows down MB tumor growth through inhibition of proliferation and enhancement of neural differentiation. These results validate Tis21 as a relevant target for MB therapy.
Collapse
Affiliation(s)
- Dario Presutti
- Institute of Cell Biology and Neurobiology, National Research Council (IBCN-CNR), Monterotondo, Rome, Italy
| | - Manuela Ceccarelli
- Institute of Cell Biology and Neurobiology, National Research Council (IBCN-CNR), Fondazione Santa Lucia, Rome, Italy
| | - Laura Micheli
- Institute of Cell Biology and Neurobiology, National Research Council (IBCN-CNR), Fondazione Santa Lucia, Rome, Italy
| | - Giuliana Papoff
- Institute of Cell Biology and Neurobiology, National Research Council (IBCN-CNR), Monterotondo, Rome, Italy
| | - Simonetta Santini
- Institute of Cell Biology and Neurobiology, National Research Council (IBCN-CNR), Monterotondo, Rome, Italy
| | - Simone Samperna
- Institute of Cell Biology and Neurobiology, National Research Council (IBCN-CNR), Monterotondo, Rome, Italy
| | - Cristiana Lalli
- Institute of Cell Biology and Neurobiology, National Research Council (IBCN-CNR), Monterotondo, Rome, Italy
| | - Lorena Zentilin
- International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, Trieste, Italy
| | - Giovina Ruberti
- Institute of Cell Biology and Neurobiology, National Research Council (IBCN-CNR), Monterotondo, Rome, Italy
- * E-mail: (GR); (FT)
| | - Felice Tirone
- Institute of Cell Biology and Neurobiology, National Research Council (IBCN-CNR), Fondazione Santa Lucia, Rome, Italy
- * E-mail: (GR); (FT)
| |
Collapse
|
3
|
Micheli L, D'Andrea G, Leonardi L, Tirone F. HDAC1, HDAC4, and HDAC9 Bind to PC3/Tis21/Btg2 and Are Required for Its Inhibition of Cell Cycle Progression and Cyclin D1 Expression. J Cell Physiol 2017; 232:1696-1707. [PMID: 27333946 DOI: 10.1002/jcp.25467] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2016] [Accepted: 06/21/2016] [Indexed: 01/23/2023]
Abstract
PC3/Tis21 is a transcriptional cofactor that inhibits proliferation in several cell types, including neural progenitors. Here, we report that PC3/Tis21 associates with HDAC1, HDAC4, and HDAC9 in vivo, in fibroblast cells. Furthermore, when HDAC1, HDAC4, or HDAC9 are silenced in fibroblasts or in a line of cerebellar progenitor cells, the ability of PC3/Tis21 to inhibit proliferation is significantly reduced. Overexpression of HDAC1, HDAC4, or HDAC9 in fibroblasts and in cerebellar precursor cells synergizes with PC3/Tis21 in inhibiting the expression of cyclin D1, a cyclin selectively inhibited by PC3/Tis21. Conversely, the depletion of HDAC1 or HDAC4 (but not HDAC9) in fibroblasts and in cerebellar precursor cells significantly impairs the ability of PC3/Tis21 to inhibit cyclin D1 expression. An analysis of HDAC4 deletion mutants shows that both the amino-terminal moiety and the catalytic domain of HDAC4 associate to PC3/Tis21, but neither alone is sufficient to potentiate the inhibition of cyclin D1 by PC3/Tis21. As a whole, our findings indicate that PC3/Tis21 inhibits cell proliferation in a way dependent on the presence of HDACs, in fibroblasts as well as in neural cells. Considering that several reports have demonstrated that HDACs can act as transcriptional corepressors on the cyclin D1 promoter, our data suggest that the association of PC3/Tis21 to HDACs is functional to recruit them to target genes, such as cyclin D1, for repression of their expression. J. Cell. Physiol. 232: 1696-1707, 2017. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Laura Micheli
- Institute of Cell Biology and Neurobiology, National Research Council, Fondazione Santa Lucia, Rome, Italy
| | - Giorgio D'Andrea
- Institute of Cell Biology and Neurobiology, National Research Council, Fondazione Santa Lucia, Rome, Italy
| | - Luca Leonardi
- Institute of Cell Biology and Neurobiology, National Research Council, Fondazione Santa Lucia, Rome, Italy
| | - Felice Tirone
- Institute of Cell Biology and Neurobiology, National Research Council, Fondazione Santa Lucia, Rome, Italy
| |
Collapse
|
4
|
Ceccarelli M, Micheli L, Tirone F. Suppression of Medulloblastoma Lesions by Forced Migration of Preneoplastic Precursor Cells with Intracerebellar Administration of the Chemokine Cxcl3. Front Pharmacol 2016; 7:484. [PMID: 28018222 PMCID: PMC5159413 DOI: 10.3389/fphar.2016.00484] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Accepted: 11/28/2016] [Indexed: 12/14/2022] Open
Abstract
Medulloblastoma (MB), tumor of the cerebellum, remains a leading cause of cancer-related mortality in childhood. We previously showed, in a mouse model of spontaneous MB (Ptch1+/-/Tis21-/-), that a defect of the migration of cerebellar granule neuron precursor cells (GCPs) correlates with an increased frequency of MB. This occurs because GCPs, rather than migrating internally and differentiating, remain longer in the proliferative area at the cerebellar surface, becoming targets of transforming insults. Furthermore, we identified the chemokine Cxcl3 as responsible for the inward migration of GCPs. As it is known that preneoplastic GCPs (pGCPs) can still migrate and differentiate like normal GCPs, thus exiting the neoplastic program, in this study we tested the hypothesis that pGCPs within a MB lesion could be induced by Cxcl3 to migrate and differentiate. We observed that the administration of Cxcl3 for 28 days within the cerebellum of 1-month-old Ptch1+/-/Tis21-/- mice, i.e., when MB lesions are already formed, leads to complete disappearance of the lesions. However, a shorter treatment with Cxcl3 (2 weeks) was ineffective, suggesting that the suppression of MB lesions is dependent on the duration of Cxcl3 application. We verified that the treatment with Cxcl3 causes a massive migration of pGCPs from the lesion to the internal granular layer, where they differentiate. Thus, the induction of migration of pGCPs in MB lesions may open new ways to treat MB that exploit the plasticity of the pGCPs, forcing their differentiation. It remains to be tested whether this plasticity continues at advanced stages of MB. If so, these findings would set a potential use of the chemokine Cxcl3 as therapeutic agent against MB development in human preclinical studies.
Collapse
Affiliation(s)
- Manuela Ceccarelli
- Genetic Control of Development, Institute of Cell Biology and Neurobiology – National Research Council, Fondazione Santa LuciaRome, Italy
| | | | - Felice Tirone
- Genetic Control of Development, Institute of Cell Biology and Neurobiology – National Research Council, Fondazione Santa LuciaRome, Italy
| |
Collapse
|
5
|
Gentile G, Ceccarelli M, Micheli L, Tirone F, Cavallaro S. Functional Genomics Identifies Tis21-Dependent Mechanisms and Putative Cancer Drug Targets Underlying Medulloblastoma Shh-Type Development. Front Pharmacol 2016; 7:449. [PMID: 27965576 PMCID: PMC5127835 DOI: 10.3389/fphar.2016.00449] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Accepted: 11/09/2016] [Indexed: 12/11/2022] Open
Abstract
We have recently generated a novel medulloblastoma (MB) mouse model with activation of the Shh pathway and lacking the MB suppressor Tis21 (Patched1+/-/Tis21KO ). Its main phenotype is a defect of migration of the cerebellar granule precursor cells (GCPs). By genomic analysis of GCPs in vivo, we identified as drug target and major responsible of this defect the down-regulation of the promigratory chemokine Cxcl3. Consequently, the GCPs remain longer in the cerebellum proliferative area, and the MB frequency is enhanced. Here, we further analyzed the genes deregulated in a Tis21-dependent manner (Patched1+/-/Tis21 wild-type vs. Ptch1+/-/Tis21 knockout), among which are a number of down-regulated tumor inhibitors and up-regulated tumor facilitators, focusing on pathways potentially involved in the tumorigenesis and on putative new drug targets. The data analysis using bioinformatic tools revealed: (i) a link between the Shh signaling and the Tis21-dependent impairment of the GCPs migration, through a Shh-dependent deregulation of the clathrin-mediated chemotaxis operating in the primary cilium through the Cxcl3-Cxcr2 axis; (ii) a possible lineage shift of Shh-type GCPs toward retinal precursor phenotype, i.e., the neural cell type involved in group 3 MB; (iii) the identification of a subset of putative drug targets for MB, involved, among the others, in the regulation of Hippo signaling and centrosome assembly. Finally, our findings define also the role of Tis21 in the regulation of gene expression, through epigenetic and RNA processing mechanisms, influencing the fate of the GCPs.
Collapse
Affiliation(s)
- Giulia Gentile
- Institute of Neurological Sciences, National Research Council Catania, Italy
| | - Manuela Ceccarelli
- Institute of Cell Biology and Neurobiology, National Research Council, Fondazione Santa Lucia Rome, Italy
| | - Laura Micheli
- Institute of Cell Biology and Neurobiology, National Research Council, Fondazione Santa Lucia Rome, Italy
| | - Felice Tirone
- Institute of Cell Biology and Neurobiology, National Research Council, Fondazione Santa Lucia Rome, Italy
| | | |
Collapse
|
6
|
Micheli L, Ceccarelli M, Farioli-Vecchioli S, Tirone F. Control of the Normal and Pathological Development of Neural Stem and Progenitor Cells by the PC3/Tis21/Btg2 and Btg1 Genes. J Cell Physiol 2015; 230:2881-90. [DOI: 10.1002/jcp.25038] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2015] [Accepted: 05/05/2015] [Indexed: 12/12/2022]
Affiliation(s)
- Laura Micheli
- Institute of Cell Biology and Neurobiology; National Research Council; Fondazione S.Lucia Rome Italy
| | - Manuela Ceccarelli
- Institute of Cell Biology and Neurobiology; National Research Council; Fondazione S.Lucia Rome Italy
| | - Stefano Farioli-Vecchioli
- Institute of Cell Biology and Neurobiology; National Research Council; Fondazione S.Lucia Rome Italy
| | - Felice Tirone
- Institute of Cell Biology and Neurobiology; National Research Council; Fondazione S.Lucia Rome Italy
| |
Collapse
|
7
|
Guo C, Chen LH, Huang Y, Chang CC, Wang P, Pirozzi CJ, Qin X, Bao X, Greer PK, McLendon RE, Yan H, Keir ST, Bigner DD, He Y. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget 2013; 4:2144-53. [PMID: 24240169 PMCID: PMC3875776 DOI: 10.18632/oncotarget.1555] [Citation(s) in RCA: 101] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2013] [Accepted: 11/01/2013] [Indexed: 01/25/2023] Open
Abstract
KMT2D (lysine (K)-specific methyltransferase 2D), formerly named MLL2 (myeloid/lymphoid or mixed-lineage leukemia 2, also known as ALR/MLL4), is a histone methyltransferase that plays an important role in regulating gene transcription. In particular, it targets histone H3 lysine 4 (H3K4), whose methylations serve as a gene activation mark. Recently, KMT2D has emerged as one of the most frequently mutated genes in a variety of cancers and in other human diseases, including lymphoma, medulloblastoma, gastric cancer, and Kabuki syndrome. Mutations in KMT2D identified thus far point to its loss-of-function in pathogenesis and suggest its role as a tumor suppressor in various tissues. To determine the effect of a KMT2D deficiency on neoplastic cells, we used homologous recombination- and nuclease-mediated gene editing approaches to generate a panel of isogenic colorectal and medulloblastoma cancer cell lines that differ with respect to their endogenous KMT2D status. We found that a KMT2D deficiency resulted in attenuated cancer cell proliferation and defective cell migration. Analysis of histone H3 modifications revealed that KMT2D was essential for maintaining the level of global H3K4 monomethylation and that its enzymatic SET domain was directly responsible for this function. Furthermore, we found that a majority of KMT2D binding sites are located in regions of potential enhancer elements. Together, these findings revealed the role of KMT2D in regulating enhancer elements in human cells and shed light on the tumorigenic role of its deficiency. Our study supports that KMT2D has distinct roles in neoplastic cells, as opposed to normal cells, and that inhibiting KMT2D may be a viable strategy for cancer therapeutics.
Collapse
Affiliation(s)
- Changcun Guo
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| | - Lee H. Chen
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| | - Yafen Huang
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| | - Chun-Chi Chang
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| | - Ping Wang
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| | - Christopher J. Pirozzi
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| | - Xiaoxia Qin
- Institute for Genome Sciences and Policy, Duke University, Durham, NC
| | - Xuhui Bao
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| | - Paula K. Greer
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| | - Roger E. McLendon
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| | - Hai Yan
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| | - Stephen T. Keir
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Surgery, Duke University, Durham, NC
| | - Darell D. Bigner
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| | - Yiping He
- The Preston Robert Tisch Brain Tumor Center at Duke and Pediatric Brain Tumor Foundation Institute, Duke University, Durham, NC
- Department of Pathology, Duke University, Durham, NC
| |
Collapse
|